Age-related Macular Degeneration (AMD)
Conditions
Keywords
First-in-human, anti-VEGF, neovascular AMD (nvAMD)
Brief summary
The purpose of this first-in-human study is to evaluate the safety and tolerability of single ascending doses of LMG324 to determine the maximum tolerated dose (MTD) in neovascular age-related macular degeneration (nvAMD) subjects. Enrollment will be expanded at a safe and tolerated dose in treatment naïve nvAMD subjects to compare a single intravitreal (IVT) dose of LMG324 to ranibizumab 0.5 mg administered every 4 weeks for change from baseline in best-corrected visual acuity (BCVA) at Week 12 (Day 85).
Detailed description
The study will start with a single dose ascending (SAD) phase. LMG324 will be administered on Day 1 with no further treatment until implementation of standard of care (SoC) therapy. SoC therapy is ranibizumab 0.5 mg administered per label. Dose groups will be implemented sequentially to allow for safety review between the current and subsequent dose group. All treatments will be open-label, including ranibizumab used as SoC therapy. In the enrollment expansion phase, subjects randomized to LMG324 arm will receive a single LMG324 IVT injection on Day 1 followed by sham (fake) IVT injections until implementation of SoC therapy. After implementation, SoC therapy will be applied monthly with sham injections applied at the interim planned visits. The enrollment expansion phase may start at a selected dose level whilst the dose escalation phase is still ongoing.
Interventions
BIOLOGICALLMG324
IVT injection
BIOLOGICALRanibizumab 0.5 mg
IVT injection
BIOLOGICALSham
Fake injection used for masking purposes
Sponsors
Novartis Institutes for BioMedical Research
Alcon Research
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must give written informed consent, be able to make the required study visits and follow instructions. * Best corrected visual acuity (BCVA) of 34 letters (approximately 20/200 Snellen or better) in the non-study eye. SAD population only: * Subject's study eye must have a choroidal neovascularization (CNV) lesion due to age-related macular degeneration (AMD), either treatment naïve or previously treated, that can be expected to benefit, in the opinion of the investigator, from anti-vascular endothelial growth factor (anti-VEGF) therapy. * Previously treated eyes must have a history of least 3 administrations of any intravitreal (IVT) anti-VEGF therapeutic for the treatment of CNV with the last injection administered ≥ 1 month prior to the planned administration of the study drug. Enrollment expansion population only * Subject's study eye must have untreated and active CNV lesion due to AMD. * BCVA, between 73 - 23 letters, inclusive (approximate Snellen equivalent 20/40 - 20/320) in the study eye.
Exclusion criteria
SAD and enrollment expansion population * Both eyes: any active ocular or periocular infection or active intraocular inflammation (eg, infectious blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis). * Study eye: current vitreous hemorrhage or a history of rhegmatogenous retinal detachment. * Study eye: uncontrolled glaucoma (intraocular pressure \[IOP\] \>25 mmHg on medication or according to Investigator's judgment). SAD population only * Presence of any contraindications, in the Investigator's opinion, to IVT anti-VEGF therapeutic administration. Enrollment expansion population only * Study eye: subject has received any approved or investigational treatment for exudative (wet) AMD other than vitamin supplements. * Study eye: any current or history of macular or retinal disease other than exudative AMD * Study eye: serous pigment epithelial detachment (PED) under the foveal center or retinal pigment epithelium (RPE) tear/rip. * Study eye: any concurrent intraocular condition (eg, cataract, diabetic retinopathy) that, in the opinion of the Investigator, could either require medical or surgical intervention during the course of the study. * Study eye: other ocular diseases that, in the opinion of the Investigator, can compromise the visual acuity * Study eye: Surgery, as specified in the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in best corrected visual acuity (BCVA) at Day 85 | Baseline, Day 85 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of LMG324-treated subjects with no identified SoC treatment need up to and including Day 85 | Up to Day 85 |
| Best Corrected Visual Acuity (BCVA) | Up to Day 169 |
| Central subfield thickness total (CSFTtot) | Up to Day 169 |
| Central subfield thickness neuro-retina (CFSTnr) | Up to Day 169 |
| Lesion thickness | Up to Day 169 |
| Subretinal fluid with foveal involvement (SRFfi) thickness | Up to Day 169 |
| Retinal pigment epithelial detachment with foveal involvement (PEDfi) thickness | Up to Day 169 |
| Area of lesion (associated with CNV) | Up to Day 169 |
| Area of CNV within a lesion | Up to Day 169 |
| Area under the plasma concentration-time curve from time zero to infinity (AUCinf) | Up to Day 169 |
| Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) | Up to Day 169 |
| Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration (AUC0-t) | Up to Day 169 |
| Maximum observed maximum plasma concentration (Cmax) | Up to Day 169 |
| Time to reach the maximum observed plasma concentration (Tmax) | Up to Day 169 |
| Observed maximum plasma concentration following drug administration, by dose (Cmax/D) | Up to Day 169 |
| Area under the plasma concentration-time curve divided by dose (AUC/D) | Up to Day 169 |
| Frequency of subjects with anti-LMG324 antibodies | Up to Day 169 |
Countries
United States
Outcome results
None listed